Transaction details
Rhea J Posedel, a director at Aehr Test Systems (NASDAQ: AEHR), sold 8,787 shares of the company’s common stock on April 21, 2026. The shares were sold at $96.0233 apiece, producing proceeds of $843,756 from the transaction.
Price context
The sale occurred as AEHR’s share price was trading close to its 52-week high of $99.67. Over the last year the stock has posted a notable gain of 1,077%.
Insider holdings after the sale
After the disposition, Ms. Posedel directly holds 62,376 shares of Aehr common stock. That direct holding figure includes shares that remain subject to unvested restricted stock units. In addition to direct ownership, she indirectly holds 396,979 shares through a trust.
Valuation commentary
InvestingPro analysis cited in company commentary indicates that AEHR currently appears overvalued relative to its Fair Value. The analysis also highlights the stock on the Most Overvalued list. Additional research resources noted include 19 ProTips and a Pro Research Report available through InvestingPro for further valuation and performance context.
Recent company developments
Separately, Aehr Test Systems disclosed that it completed a $60 million at-the-market (ATM) common stock offering, as reported in a filing with the Securities and Exchange Commission. The company also announced a record production order valued at $41 million from a hyperscale customer. That order, for package-level burn-in of custom AI processor ASICs, includes high-power test systems and modules and is the largest order in the company’s history. Deliveries for that order are scheduled to begin in fiscal 2027.
Analyst moves and financials
On the analyst front, Freedom Broker raised its price target on Aehr Test Systems to $61 while keeping a Hold rating, citing strong bookings. Lake Street also raised its price target to $56 and maintained a Buy rating, pointing to robust booking momentum as a supporting factor.
For the third quarter of fiscal 2026, Aehr Test Systems reported revenue of $10.3 million, a result described as slightly below consensus estimates. The quarter also produced record quarterly bookings of $37.2 million. Management reported an effective backlog that exceeded $50 million and highlighted a book-to-bill ratio in excess of 3.5x.
What is known and what is not
The facts above reflect filings and company reports: the precise insider sale, the company’s capital raise, the record production order, analyst price target changes, and quarterly results and bookings. The public record included an InvestingPro fairness assessment and pointers to additional paid research materials.
Investors and market participants may weigh the insider sale in the context of the company’s recent capital activity and strong booking cadence. The data reported here are limited to the specific disclosures and analysis cited and do not attempt to draw conclusions beyond those statements.